Legend Biotech Corp Revenue From Contracts With Customers
Legend Biotech Corp (LEGN) reported Revenue From Contracts With Customers of $1.03 billion for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Income Statement › Other Income
ifrs-full:RevenueFromContractsWithCustomers · last filed 2026-03-10
- Legend Biotech Corp revenue from contracts with customers for the quarter ending 2025-12-31 was $973.54M, a 94.26% increase year-over-year.
- Legend Biotech Corp revenue from contracts with customers for the quarter ending 2025-09-30 was $10.50M, a 39.58% decline year-over-year.
- Legend Biotech Corp revenue from contracts with customers for the quarter ending 2025-06-30 was $35.34M, a 62.11% decline year-over-year.
- Legend Biotech Corp revenue from contracts with customers for the quarter ending 2025-03-31 was $9.44M, a 39.15% decline year-over-year.
| Period end | Revenue From Contracts With Customers 3 month | Revenue From Contracts With Customers 6 month | Revenue From Contracts With Customers 9 month | Revenue From Contracts With Customers 12 month | Revenue From Contracts With Customers 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $973.54M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $984.04M derived: sum of 2 quarters · filed 2026-03-10 | $1.02B derived: sum of 3 quarters · filed 2026-03-10 | $1.03B 20-F · filed 2026-03-10 | |
| 2025-09-30 | $10.50M 6-K · filed 2025-11-12 | $45.84M derived: sum of 2 quarters · filed 2025-11-12 | $55.36M 6-K · filed 2025-11-12 | $556.42M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $35.34M 6-K · filed 2025-08-11 | $44.78M 6-K · filed 2025-08-11 | $545.92M derived: sum of 3 quarters · filed 2026-03-10 | $563.30M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $9.44M 6-K · filed 2025-05-13 | $510.58M derived: sum of 2 quarters · filed 2026-03-10 | $527.96M derived: sum of 3 quarters · filed 2026-03-10 | $621.23M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $501.14M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $518.52M derived: sum of 2 quarters · filed 2026-03-10 | $611.79M derived: sum of 3 quarters · filed 2026-03-10 | $627.30M 20-F · filed 2026-03-10 | $144.66M 20-F · filed 2025-03-11 |
| 2024-09-30 | $17.38M 6-K · filed 2025-11-12 | $110.65M derived: sum of 2 quarters · filed 2025-11-12 | $126.16M 6-K · filed 2025-11-12 | $205.58M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $93.27M 6-K · filed 2025-08-11 | $108.78M 6-K · filed 2025-08-11 | $188.20M derived: sum of 3 quarters · filed 2026-03-10 | $284.21M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $15.51M 6-K · filed 2025-05-13 | $94.93M derived: sum of 2 quarters · filed 2026-03-10 | $190.94M derived: sum of 3 quarters · filed 2026-03-10 | ||
| 2023-12-31 | $79.42M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $175.43M derived: sum of 2 quarters · filed 2026-03-10 | $285.10M 20-F · filed 2026-03-10 | $35.34M 20-F · filed 2024-03-19 | |
| 2023-09-30 | $96.01M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $205.68M 6-K · filed 2023-11-20 | |||
| 2023-06-30 | $109.67M 6-K · filed 2023-08-15 | ||||
| 2022-12-31 | -$39.04M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | -$11.68M derived: sum of 2 quarters · filed 2025-03-11 | $50.33M 20-F · filed 2025-03-11 | $117.00M 20-F · filed 2023-03-30 | |
| 2022-09-30 | $27.36M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $89.37M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $62.01M 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $68.83M 20-F · filed 2024-03-19 | $89.79M 20-F · filed 2022-03-31 | |||
| 2021-06-30 | $33.91M 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $75.00M 20-F · filed 2023-03-30 | $75.68M 20-F · filed 2021-04-02 | |||
| 2020-06-30 | $23.15M 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $59.98M 20-F/A · filed 2023-02-17 | $57.26M 20-F · filed 2021-04-02 | |||
| 2018-12-31 | $49.13M 20-F · filed 2021-04-02 |